SALISBURY UNIVERSITY STUDENT HEALTH SERVICES

CLINICAL ASSESSMENT OF TUBERCULOSIS BY HEALTH CARE PROVIDER

This form must be completed and signed by a health care provider.

UPLOAD INTO THE SECURE STUDENT HEALTH WEB PORTAL: myhealth.salisbury.edu

Salisbury University Student Health Services, Holloway Hall Room 180, 1101 Camden Avenue, Salisbury, MD 21801 FAX: 410-548-4101 • EMAIL: studenthealth@salisbury.edu

Name: (Last)	
	Date of Birth:
Address:	
International Student:	
Clinical Assessment of Tu	berculosis by Health Care Provider
Persons answering YES to any of the questions in the Tuberculosis Screening Questionno (IGRA), unless a previous positive test has been documented.	ire are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay
History of a positive TB skin test or IGRA blood test? (If yes, document below)	YESNO
Previous or current treatment for Tuberculosis (If yes, please provide details	_YESNO
History of BCG vaccination? (If yes, consider IGRA.)YESNO	
1. TB SYMPTOM CHECK:	Salisbury
Does the student have signs or symptoms of active pulmonary tuberculosis disease? _ If No, proceed to 2 or 3 If yes, check below:	* Interpretation guidelines
 □ Cough (especially if lasting for 3 weeks or longer) with or without sputum productio □ Coughing up blood (hemoptysis) 	 >5 mm is positive: Recent close contacts of an individual with infectious TB
Chest pain	Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
☐ Loss of appetite	Organ transplant recipients and other immunosuppressed persons
☐ Unexplained weight loss	(including receiving equivalent of >15 mg/d of prednisone for >1 month)
☐ Night sweats ☐ Fever	HIV-infected persons
Proceed with additional evaluation to exclude active tuberculosis disease including tuber skin testing, chest x-ray and sputum evaluation as indicated.	>10 mm is positive: • Recent arrivals to the U.S. (<5 years) from high-prevalence areas or who resided in one for a significant** amount of time
2. Tuberculin Skin Test (TST)	Injection drug users
(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0." The TST interpretation should be based on mm of induration as well as risk factors.)* Date Given:/ Date Read:/ M / D / Y	 Mycobacteriology laboratory personnel Residents, employees or volunteers in high-risk congregate settings Persons with medical conditions that increase the risk of progression to TB disease, including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight
Result: mm of induration **Interpretation: Positive Negative	>15 mm is positive:
Date Given:/ Date Read:/ M / D / Y	 Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested. **Populations defined locally as having an increased incidence of disease due to M. tuberculosis, including medically underserved, low-income populations
Result: mm of induration *Interpretation: Positive Negative	V ,

3. Interferon Gamma Release Assay (IGRA)
Date Obtained:/ (specify method) QFT-GIT T-Spot Other
Result: Negative Positive Indeterminate Borderline (T-Spot only)
Date Obtained:/ (specify method) QFT-GIT T-Spot Other
Result: negative Positive Indeterminate Borderline (T-Spot only)
4. Chest X-ray: (Required if TST or IGRA is positive)
Date of chest x-ray:/ Result: Normal Abnormal
Management of Positive TST or IGRA
All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.
□ Infected with HIV
□ Recently infected with M. tuberculosis (within the past 2 years)
□ History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
 Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
□ Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck or lung
□ Have had a gastrectomy or jejunoileal bypass
□ Weigh less than 90% of their ideal body weight
□ Cigarette smokers and persons who abuse drugs and/or alcohol
Student agrees to receive treatment
Student declines treatment at this time*
*Per recommendations set forth by the American College Health Association, any student who declines treatment will be asked to repeat a chest x-ray every two years while enrolled at Salisbury University.
Healthcare Provider Name (please print):
Healthcare Provider Signature: Date:
Provider Address:

FORM MUST BE SIGNED AND STAMPED BY HEALTH CARE OFFICE OR IT WILL NOT BE ACCEPTED.